A Phase I Study of Bevacizumab (B) in Combination with Everolimus (E) and Erlotinib (E) in Advanced Cancer (BEE)

PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus and erlotinib combination. METHODS: Doublet therapy consisted of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bullock, Karen E., Petros, William P., Younis, Islam, Uronis, Hope E., Morse, Michael A., Blobe, Gerard C., Zafar, S. Yousuf, Gockerman, Jon P., Lager, Joanne J., Truax, Roxanne, Meadows, Kellen L., Howard, Leigh A., O’Neill, Margot M., Broadwater, Gloria, Hurwitz, Herbert I., Bendell, Johanna C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086252/
https://ncbi.nlm.nih.gov/pubmed/21079958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1507-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller